Comparison of immunogenicity of anti-HBV vaccination end serovaccination in alcoholic patients with cirrhosis;Comparaison de l'immunogenicite de la vaccination et de la serovaccination contre le virus de l'hepatite B chez les malades atteints de cirrhose alcoolique

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 11, 1997, Pages 848-853

  Bronowicki, Jean Pierre ^a   Weber Larivaille, Florence ^a   Gut, Jean Pierre ^a   Doffoël, Michel ^a   Vetter, Denis ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Alcohol; Cirrhosis; Hepatitis B virus; Immunoglobulins; Serovaccination; Vaccination

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN;

ACTIVE IMMUNIZATION; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENTIATION; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MALE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; COMPARATIVE STUDY; IMMUNOGENETICS; IMMUNOLOGY; MIDDLE AGED; PASSIVE IMMUNIZATION; PROSPECTIVE STUDY; VACCINATION;

FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGENETICS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINATION;

EID: 0031325474     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Vargas V, Pedreira JD, Vilaseca J, Ruiz J, Esteban R, Hernandez JM, et al. Hepatocellular carcinoma and hepatitis B virus markers in Europe. Lancet 1979;31:721-2.
2. Beaugrand M, Dupont T, Ferrier JP, Couroucé AM. Etude des marqueurs sériques du virus B chez 77 malades atteints de cirrhose alcoolique comparés à des témoins (résumé). Gastroenterol Clin Biol 1980;4:89A.
3. Attali P, Thibault N, Buffet C, Briantais MJ, Papoz L, Chaput JC, et al. Les marqueurs du virus B chez les alcooliques chroniques. Gastroenterol Clin Biol 1981;5:1095-102.
4. Goudeau A, Maupas P, Dubois F, Coursaget P, Bougnoux P. Hepatitis B infection in alcoholic liver disease and primary hepatocellular carcinoma in France. Prog Med Virol 1981;27:26-34.
5. Orholm M, Aldershvile J, Tage-Jensen U, Schlichting P, Nielsen JO, Hardt F, et al. Prevalence of hepatitis B virus infection among alcoholic patients with liver disease. J Clin Pathol 1981;34:1378-80.
6. Chalmers DM, Bullen AW, Levi AJ. Evidence for previous hepatitis B virus infection in alcoholic cirrhosis. Br Med J 1981;282:819.
7. Hislop WS, Follett EAC, Bouchier IAD, MacSween RNM. Serological markers of hepatitis B in patients with alcoholic liver disease: a multi-centre survey. J Clin Pathol 1981;34:1017-9.
8. Mills PR, Follett EAC, Urquhart GED, Clements G, Watkinson G, MacSween RNM. Evidence for previous hepatitis B virus infection in alcoholic cirrhosis. Br Med J 1981;282:437-8.
9. Coste T, Gie A, Fischer D, Karsenti P, Paraf A. Fréquence des marqueurs du virus B chez les alcooliques chroniques avec ou sans cirrhose. Gastroenterol Clin Biol 1982;6:515-6.
10. Saunders JB, Wodak AD, Morgan-Capner P, White YS, Portmann B, Davis M, et al. Importance of markers of hepatitis B virus in alcoholic liver disease. Br Med J 1983;286:1851-4.
11. Chevillotte G, Durbec JP, Gerolami A, Berthezène P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis. An epidemiologic study. Gastroenterology 1983;85:141-5.
12. Bassendine MF, Della Seta L, Salmeron J, Thomas HC, Sherlock S. Incidence of hepatitis B virus infection in alcoholic liver disease, HBsAg negative chronic active liver disease and primary liver cell cancer in Britain. Liver 1983;3:65-70.
13. Stigendal L, Hermodsson S, Olsson R. Prevalence of markers of hepatotropic viruses in alcoholics with symptomatic liver cirrhosis or pancreatitis. Scand J Gastroenterol 1984;19:588-90.
14. Inoue K, Kojima T, Koyata H, Malsui S, Aoyama K, Konda T, et al. Hepatitis B virus antigen and antibodies in alcoholics. Etiological role of HBV in liver diseases of alcoholic patients. Liver 1985;5:247-52.
15. Vetter D, Doffoel M, Gut JP, Doffoel S, North ML, Charrault A, et al. Virus de l'hépatite B, marqueurs sérologiques d'infections virales et immunité humorale au cours de la cirrhose alcoolique. Gastroenterol Clin Biol 1985;9:389-95.
16. Bailly D, Dervaux A, Parquet PJ. Le problème de la vaccination contre l'hépatite B chez les alcooliques. A propos d'une enquête préliminaire en milieu hospitalier. Sem Hop Paris 1986;62:1779-84.
17. Doffoël M, Tongio MM, Gut JP, Ventre G, Charrault A, Vetter D, et al. Relationships between 34 HLA-A, HLA-B and HLA-DR antigens and three serological markers of viral infections in alcoholic cirrhosis. Hepatology 1986;6:457-66.
18. Fong TL, Govindarajan S, Valinluck B, Redeker AG. Status of hepatitis B virus DNA in alcoholic liver disease: a study of a large urban population in the United States. Hepatology 1988;8:1602-4.
19. Feller A, Uchida T, Rakela J. Acute viral hepatitis superimposed on alcoholic liver cirrhosis: clinical and histopathologic features. Liver 1985;5:239-46.
20. Pelletier G, Versapuech JM, Ink O, Labayle D, Chaput JC, Etienne JP. Pronostic des hépatites virales aiguës survenant chez des malades atteints de cirrhose alcoolique. Gastroenterol Clin Biol 1987;11:409-11.
21. Bréchot C, Nalpas B, Couroucé AM, Duhamel G, Callard P, Carnot F, et al. Evidence that hepatitis B virus has a role in liver cell carcinoma in alcoholic liver disease. N Engl J Med 1982;306:1384-7.
22. Bréchot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270-6.
23. Van Thiel DH, El-Ashmawy L, Love K, Gavaler JS, Starzl TE. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992;37:1245-9.
24. Degos F, Duhamel G, Bréchot C, Nalpas B, Couroucé AM, Tron F, et al. Hepatitis B vaccination in chronic alcoholics. J Hepatol 1986;2:402-9.
25. Degos F, Duhamel G. Vaccination contre le virus B et cirrhose alcoolique. Gastroenterol Clin Biol 1986;10:629-32.
26. Mendenhall C, Roselle GA, Lybecker LA, Marshall LE, Grossman CJ, Myre SA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci 1988;33:263-9.
27. Nalpas B, Thépot V, Driss F, Pol S, Couroucé AM, Saliou P, et al. Secondary immune response to hepatitis B virus vaccine in alcoholics. Alcohol Clin Exp Res 1993;17:295-9.
28. Celis E, Chang TW. HBsAg-serum protein complexes stimulate immune T lymphocytes more efficiently than do pure HBsAg. Hepatology 1984;4:1116-23.
29. Celis E, Chang TW. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 1984;224:297-9.
30. Cells E, Kato I, Miller RW, Chang TW. Regulation of the human immune response to HBsAg: effects of antibodies and antigen conformation in the stimulation of helper T cells by HBsAg. Hepatology 1985;5:744-51.
31. Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 1987;7:563-8.
32. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni ME, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
33. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to the hepatitis B surface antigen carriage. Cancer 1982;49:672-7.
34. Coursaget P, Adamowicz P, Bourdil C, Yvonnet B, Buisson Y, Barres JL, et al. Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization. Vaccine 1988;6:357-61.
35. Zanetti A, Tanzi E, Mannucci PM. Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs. J Med Virol 1989;28:156-8.
36. Lelie PN, Niessen J, Oehlers PJ. Heat treatment and addition of anti-HBs antibodies potentiate the immunogenicity of a plasma-derived HBs-Ag vaccine. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988:1009-13.
37. Quiroga JA, Castillo I, Porres JC, Casado S, Saez F, Martinez MG, et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990;12:661-3.
38. Meuer SC, Dumann H, Meyer zum Büschenfelde KH, Köhler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989;1:15-8.
39. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1988;50:133-6.
40. Lelie PN, Van Amelsfoort PJAJ, De Groot CSM, Bakker E, Schaasberg W, Niessen JCM, et al. Lack of immune potentiation by complexing HBsAg in a heat-inactivated hepatitis B vaccine with antibody in hepatitis B immunoglobulin. Hepatology 1989;10:36-8.
41. Minuk GY, German GB, Bernstein KN, Fine A, Schroeder ML, Wong WWS. Failure of passively administered antibody to hepatitis B surface antigen to augment the immune response of low-responder population to hepatitis B vaccination. Clin Invest Med 1994;17:61-5.
42. Corradin G, Engers HD. Inhibition of antigen-induced T-cell clone proliferation by antigen-specific antibodies. Nature 1984;308:547-8.
43. Milich DR, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg): I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J Immunol 1982;129:320-5.
44. Milich DR, Leroux-Roels GG, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg): II. Qualitative characteristics of the humoral immune response to the a, d, and y determinants of HBsAg. J Immunol 1983;130:1395-400.
45. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, et al. Non responsiveness to hepatitis B vaccine in health care workers. Ann Intern Med 1986;105:356-60.
46. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in non responders to the plasma vaccine. JAMA 1988;260:1734-8.
47. Marescot MR, Budkowska A, Pillot J, Debre P. HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination. Tissue Antigens 1989;33:495-500.
48. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of non response to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990;11:385-7.
49. Stachowski J, Kramer J, Fust G, Maciejewski J, Baldamus CA, Petranyi GG. Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand J Immunol 1995;42:60-5.
50. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-12.
51. Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci USA 1985;82:8168.
52. Gesemann M, Scheiermann N, Brockmeyer N. Clinical evaluation of a recombinant hepatitis B vaccine in HIV-infection vs uninfected persons. In: Zuckermann AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss,1988:998-1001.
53. Lee SD, Tong MJ. Correlation between peripheral lymphocyte subsets and antibody to hepatitis B surface antigen response in hepatitis B recipients. Scand J Infect Dis 1985;17:333-5.
54. Nowicki MJ, Tong MJ, Bohman RE. Alterations in the immune response of non responders to hepatitis B vaccine. J Infect Dis 1985;152:1245-8.